Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 2:40 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–402 of 402 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: PAH Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Subcutaneous Elafin in Healthy Subjects

NCT03522935
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Elafin, Placebo
Drug
Lead sponsor
Roham T. Zamanian
Other
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 15, 2024 · Synced Oct 24, 2026, 2:40 AM EDT
Recruiting No phase listed Observational

Right Ventricle Lipid in Pulmonary Arterial Hypertension (PAH)

NCT05462574
View directory record Official record
Conditions
Idiopathic Pulmonary Arterial Hypertension, Heritable Pulmonary Arterial Hypertension, Pulmonary Arterial Hypertension Associated With Connective Tissue Disease
Interventions
No Intervention
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 24, 2026, 2:40 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Dose Escalation, MTD, Safety and PK Study of a Single Dose SC Injection of TransCon PEG Treprostinil in Healthy Male Volunteers

NCT02149095
View directory record Official record
Conditions
PAH
Interventions
TransCon PEG treprostinil
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years to 50 Years · Male only
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2014
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 7, 2014 · Synced Oct 24, 2026, 2:40 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Fluoxetine in Pulmonary Arterial Hypertension (PAH) Trial

NCT03638908
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Fluoxetine
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
16 Years to 80 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 26, 2020 · Synced Oct 24, 2026, 2:40 AM EDT
Completed No phase listed Observational

Epidemiology and Treatment Patterns of Paediatric PAH (Pulmonary Arterial Hypertension)

NCT02576002
View directory record Official record
Conditions
Hypertension, Pulmonary
Interventions
Assigned pulmonary hypertension medication
Drug
Lead sponsor
Bayer
Industry
Eligibility
Up to 18 Years
Enrollment
2,691 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 26, 2016 · Synced Oct 24, 2026, 2:40 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Pulmonary Vascular Disease Phenomics Program PVDOMICS

NCT02980887
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
No Intervention
Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 100 Years
Enrollment
1,195 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2029
U.S. locations
7
States / cities
Tucson, Arizona • Baltimore, Maryland • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 24, 2026, 2:40 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Rutgers University Study of the Genetics of Pulmonary Hypertension

NCT07217522
View directory record Official record
Conditions
Pulmonary Hypertension, Pulmonary Arterial Hypertension, Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH), Pulmonary Arterial Hypertension Associated With Connective Tissue Disease, Pulmonary Arterial Hypertension Associated With Connective Tissue Disease (Disorder), Pulmonary Arterial Hypertension Associated With Schistosomiasis (Disorder), Pulmonary Arterial Hypertension of Congenital Heart Disease, Pulmonary Arterial and Chronic Thromboembolic Pulmonary Hypertension
Interventions
Saliva sample, Health surveys
Genetic · Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
10,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Piscataway, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Oct 24, 2026, 2:40 AM EDT
Completed Phase 3 Interventional

A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients

NCT03626688
View directory record Official record
Conditions
PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension, Connective Tissue Diseases, Familial Primary Pulmonary Hypertension, Vascular Diseases, Cardiovascular Diseases, Hypertension, Pulmonary, Lung Diseases, Respiratory Tract Disease
Interventions
Ralinepag, Placebo
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
687 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
68
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 50 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 24, 2026, 2:40 AM EDT
Recruiting Phase 2 Interventional

Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)

NCT05587712
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Sotatercept
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
1 Year to 17 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
10
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 24, 2026, 2:40 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Symptomatic Pulmonary Arterial Hypertension After Mitral Valve Surgery

NCT01646541
View directory record Official record
Conditions
Pulmonary Hypertension, Mitral Valve Disease
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
2
States / cities
Chicago, Illinois • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 3, 2017 · Synced Oct 24, 2026, 2:40 AM EDT
Terminated Phase 3 Interventional Results available

A Study With BPS-314d-MR-PAH-303 in Participants With Pulmonary Arterial Hypertension

NCT03657095
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Esuberaprost, Placebo
Drug
Lead sponsor
Lung Biotechnology PBC
Industry
Eligibility
18 Years to 85 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
43
States / cities
Birmingham, Alabama • Beverly Hills, California • La Jolla, California + 37 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2020 · Synced Oct 24, 2026, 2:40 AM EDT
Completed Phase 1 Interventional Results available

Open-label, Clinical Study to Evaluate the Safety and Tolerability of TreT in Subjects With PAH Currently Using Tyvaso

NCT03950739
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Treprostinil Inhalation Powder
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
16
States / cities
Birmingham, Alabama • Los Angeles, California • Jacksonville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2024 · Synced Oct 24, 2026, 2:40 AM EDT
Completed No phase listed Observational

Dysregulation of Lipid Metabolism and Right Ventricular Function in PAH

NCT02631421
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Blood Sampling, Cardiac MRI
Procedure · Other
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 16, 2019 · Synced Oct 24, 2026, 2:40 AM EDT
Terminated Phase 2 Interventional Results available

Safety, Pharmacokinetics and Efficacy Study of QCC374 in PAH Patients

NCT02927366
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
QCC374, Placebo Matching
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 24, 2026, 2:40 AM EDT
Completed Phase 3 Interventional Results available

A Study of Tadalafil in Pediatric Participants With Pulmonary Arterial Hypertension (PAH)

NCT01824290
View directory record Official record
Conditions
Hypertension, Pulmonary
Interventions
Tadalafil, Placebo, ERA as specific PAH treatment
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
6 Months to 17 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
7
States / cities
Atlanta, Georgia • Detroit, Michigan • Cincinnati, Ohio + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2021 · Synced Oct 24, 2026, 2:40 AM EDT
Active, not recruiting Phase 2 Interventional

A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489

NCT07073820
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
PF-07868489
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
4
States / cities
San Francisco, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 24, 2026, 2:40 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Assessmet of Patients With PAH Right Ventricular Volume

NCT01557582
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Ventripoint Medical System
Device
Lead sponsor
VentriPoint Diagnostics Ltd.
Industry
Eligibility
12 Years and older
Enrollment
103 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
6
States / cities
Chicago, Illinois • Boston, Massachusetts • Rochester, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2015 · Synced Oct 24, 2026, 2:40 AM EDT
Active, not recruiting Not applicable Interventional

Home Rehabilitation Improves Cardiac Effort in Pulmonary Arterial Hypertension

NCT06477640
View directory record Official record
Conditions
Pulmonary Arterial Hypertension PAH
Interventions
Exercise, Standard of Care
Behavioral
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 24, 2026, 2:40 AM EDT